journal
https://read.qxmd.com/read/38613241/a-safety-and-efficacy-study-of-allogeneic-haematopoietic-stem-cell-transplantation-for-refractory-and-relapsed-t-cell-acute-lymphoblastic-leukaemia-lymphoblastic-lymphoma-patients-who-achieved-complete-remission-after-autologous-cd7-chimeric-antigen-receptor
#1
JOURNAL ARTICLE
Xing-Yu Cao, Jian-Ping Zhang, Yue Lu, Yan-Li Zhao, De-Yan Liu, Min Xiong, Rui-Juan Sun, Zhi-Jie Wei, Jia-Rui Zhou, Xian Zhang, Jun-Fang Yang, Jingjing Li, Peihua Lu
CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T-ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T-ALL/LBL who underwent allo-HSCT after achieving CR with autologous CD7 CAR-T therapy...
April 13, 2024: British Journal of Haematology
https://read.qxmd.com/read/38613165/peripheral-t-cell-lymphomas-expressing-cd30-and-cd15-expand-the-spectrum-of-anaplastic-large-cell-lymphoma-alk-negative
#2
JOURNAL ARTICLE
Karthik A Ganapathi, Alina Nicolae, Caoimhe Egan, Huimin Geng, Liqiang Xi, Svetlana D Pack, Jason R McFadden, Mark Raffeld, Elaine S Jaffe, Stefania Pittaluga
Peripheral T-cell lymphomas (PTCL) are morphologically and biologically heterogeneous and a subset expresses CD30, including anaplastic large cell lymphomas (ALCL) and a minority of PTCL, not otherwise specified (PTCL, NOS). ALCL with ALK translocations (ALCL, ALK+) are readily identified by routine diagnostic methods, but differentiating ALCL without ALK translocation (ALCL, ALK-) and PTCL, NOS expressing CD30 (PTCL CD30+) can be challenging. Furthermore, rare PTCL co-express CD30 and CD15 (PTCL CD30+CD15+); some resemble ALCL, ALK- while others resemble classic Hodgkin lymphoma...
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38613149/proteomic-profiling-of-circulating-%C3%AE-thalassaemia-haemoglobin-e-extra-cellular-vesicles-reveals-that-association-with-immunoglobulin-induces-membrane-vesiculation
#3
JOURNAL ARTICLE
Kunwadee Phongpao, Nuttanan Pholngam, Daranee Chokchaichamnankit, Khanita Nuamsee, Rattanaporn Praneetponkang, Puey Ounjai, Kittiphong Paiboonsukwong, Panjaree Siwaponanan, Kovit Pattanapanyasat, Jisnuson Svasti, Chantragan Srisomsap, Churat Weeraphan, Pornthip Chaichompoo, Saovaros Svasti
Splenectomised β-thalassaemia/haemoglobin E (HbE) patients have increased levels of circulating microparticles or medium extra-cellular vesicles (mEVs). The splenectomised mEVs play important roles in thromboembolic complications in patients since they can induce platelet activation and endothelial cell dysfunction. However, a comprehensive understanding of the mechanism of mEV generation in thalassaemia disease has still not been reached. Thalassaemic mEVs are hypothesised to be generated from cellular oxidative stress in red blood cells (RBCs) and platelets...
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38613141/mixed-histiocytic-neoplasms-a-multicentre-series-revealing-diverse-somatic-mutations-and-responses-to-targeted-therapy
#4
JOURNAL ARTICLE
Joshua S Friedman, Benjamin H Durham, Anne S Reiner, Mariko Yabe, Kseniya Petrova-Drus, Ahmet Dogan, Melissa Pulitzer, Klaus J Busam, Jasmine H Francis, Raajit K Rampal, Gary A Ulaner, Ryan Reddy, Randy Yeh, Vaios Hatzoglou, Mario E Lacouture, Veronica Rotemberg, Roei D Mazor, Oshrat Hershkovitz-Rokah, Ofer Shpilberg, Gaurav Goyal, Ronald S Go, Jithma P Abeykoon, Karen Rech, Diana Morlote, Shiraz Fidai, Vedavyas Gannamani, Maryam Zia, Omar Abdel-Wahab, Katherine S Panageas, Marc K Rosenblum, Eli L Diamond
Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai-Dorfman-Destombes disease (RDD) and Erdheim-Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders...
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38607668/variants-leading-to-dysfibrinogenaemia-in-the-fibrinogen-%C3%AE-chain-at-residue-arg19-are-not-solely-associated-with-bleeding-but-also-with-thrombotic-events-response
#5
LETTER
Radha Ramanan, James D McFadyen, Andrew C Perkins, Huyen A Tran
No abstract text is available yet for this article.
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38607667/variants-leading-to-dysfibrinogenaemia-in-the-fibrinogen-%C3%AE-chain-at-residue-arg19-are-not-solely-associated-with-bleeding-but-also-with-thrombotic-events
#6
LETTER
Mustafa Vakur Bor
No abstract text is available yet for this article.
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38606542/from-mutation-to-management-advancing-langerhans-cell-histiocytosis-treatment-through-combination-therapies
#7
JOURNAL ARTICLE
Akiva Diamond
The treatment landscape for relapsed Langerhans cell histiocytosis (LCH) is fraught with uncertainty due to a scarcity of data. Karri et al.'s study provides promising evidence that combining MAPK pathway inhibitors with chemotherapy could improve outcomes, even for patients with multiple relapses. Although larger studies are needed, this approach suggests a shift towards more aggressive, potentially curative strategies in the management of LCH. Commentary on: Karri et al. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis...
April 12, 2024: British Journal of Haematology
https://read.qxmd.com/read/38603594/characteristics-and-outcomes-of-acute-myeloid-leukaemia-patients-with-baseline-cd7-expression
#8
JOURNAL ARTICLE
Wei-Ying Jen, Koji Sasaki, Sanam Loghavi, Sa A Wang, Wei Qiao, Gautam Borthakur, Farhad Ravandi, Tapan M Kadia, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Naval G Daver, Courtney D DiNardo
Targeted therapy development for acute myeloid leukaemia (AML) requires an understanding of specific expression profiles. We collected flow cytometry data on 901 AML patients and recorded aberrant CD7 expression on leukaemic blasts. 263 (29.2%) had blasts positive for CD7. CD7+ AML was more likely to be adverse risk (64.6% vs. 55.6%, p = 0.0074) and less likely to be favourable risk (15.2% vs. 24.1%, p = 0.0074) by European LeukemiaNet 2022 criteria. Overall survival was inferior (11...
April 11, 2024: British Journal of Haematology
https://read.qxmd.com/read/38602310/revisiting-the-most-often-used-item-in-the-haematological-tool-box-the-extent-of-haemodilution-in-bone-marrow-aspirates
#9
JOURNAL ARTICLE
Peter Hokland
In this issue, a nationwide retrospective Japanese study finds that, in a second opinion setting, one-third of bone marrow aspirates from patients suspected of myelodysplastic syndromes are heavily haemodiluted. Moreover, in four-fifths of such cases, the failure to obtain the correct material for diagnosis went undetected by the referring institution. These data are intriguing, but given their special set-up, caution should be exerted in transposing them to other countries. Commentary on: Ogata et al...
April 11, 2024: British Journal of Haematology
https://read.qxmd.com/read/38602216/strategies-to-reduce-relapse-risk-in-patients-undergoing-allogeneic-stem-cell-transplantation-for-acute-myeloid-leukaemia
#10
REVIEW
Francesca A M Kinsella, Maria A L Maroto, Justin Loke, Charles Craddock
Allogeneic stem cell transplantation is a centrally important curative strategy in adults with acute myeloid leukaemia; however, relapse occurs in a significant proportion of patients and remains the leading cause of treatment failure. The prognosis for patients who relapse post-transplant remains poor, and the development of new strategies with the ability to reduce disease recurrence without increasing transplant toxicity remains a priority. In this review, within the context of our understanding of disease biology and the graft-versus-leukaemia (GVL) effect, we will discuss established, evolving and novel approaches for increasing remission rates, decreasing measurable residual disease pretransplant, future methods to augment the GVL effect and the opportunities for post-transplant maintenance...
April 11, 2024: British Journal of Haematology
https://read.qxmd.com/read/38600802/british-society-for-haematology-guidelines-to-improve-the-care-of-asplenic-patients-much-work-done-some-remaining-and-a-call-for-national-registries
#11
JOURNAL ARTICLE
Etienne Rivière
Asplenic patients are at high risk of serious infectious or thrombotic complications, especially when they are not adequately informed of the risk and not closely followed. Ladhani et al. on behalf of the British Society for Haematology propose updated guidelines for managing these patients. Healthcare professionals need to improve infection prevention in patients with hypofunctional or absent spleen through better identification and immunisation using established national registries. Commentary on: Ladhani et al...
April 10, 2024: British Journal of Haematology
https://read.qxmd.com/read/38600782/prevention-and-treatment-of-infection-in-patients-with-an-absent-or-hypofunctional-spleen-a-british-society-for-haematology-guideline
#12
JOURNAL ARTICLE
Shamez N Ladhani, Savio Fernandes, Mamta Garg, Ray Borrow, Simon de Lusignan, Paula H B Bolton-Maggs
Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were published by the British Committee for Standards in Haematology in 1996 and updated in 2002 and 2011. With advances in vaccinations and changes in patterns of infection, the guidelines required updating. Key aspects included in this guideline are the identification of patients at risk of infection, patient education and information and immunisation schedules. This guideline does not address the non-infective complications of splenectomy or functional hyposplenism (FH)...
April 10, 2024: British Journal of Haematology
https://read.qxmd.com/read/38594876/outcome-and-feasibility-of-radiotherapy-bridging-in-large-b-cell-lymphoma-patients-receiving-cd19-car-t-in-the-uk
#13
JOURNAL ARTICLE
A Kuhnl, C Roddie, A A Kirkwood, S Chaganti, J Norman, S Lugthart, W Osborne, A Gibb, C Gonzalez Arias, A Latif, B Uttenthal, F Seymour, C Jones, D Springell, J L Brady, T Illidge, A Stevens, E Alexander, L Hawley, N O'Rourke, C Bedi, R Prestwich, J Frew, D Burns, M O'Reilly, R Sanderson, S Sivabalasingham, N G Mikhaeel
Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT)...
April 9, 2024: British Journal of Haematology
https://read.qxmd.com/read/38594875/actn1-related-thrombocytopenia-homozygosity-for-an-actn1-variant-results-in-a-more-severe-phenotype
#14
JOURNAL ARTICLE
Melania Eva Zanchetta, Serena Barozzi, Federica Isidori, Caterina Marconi, Loredana Farinasso, Roberta Bottega, Anna Savoia, Alessandro Pecci, Michela Faleschini
ACTN1-related thrombocytopenia is a rare disorder caused by heterozygous variants in the ACTN1 gene characterized by macrothrombocytopenia and mild bleeding tendency. We describe for the first time two patients affected with ACTN1-RT caused by a homozygous variant in ACTN1 (c.982G>A) with mild heart valve defects unexplained by any other genetic variants investigated by WES. Within the reported family, the homozygous sisters have moderate thrombocytopenia and marked platelet macrocytosis with giant platelets, revealing a more severe haematological phenotype compared to their heterozygous relatives and highlighting a significant effect of allelic burden on platelet size...
April 9, 2024: British Journal of Haematology
https://read.qxmd.com/read/38593353/gemtuzumab-ozogamicin-plus-midostaurin-in-combination-with-standard-7%C3%A2-%C3%A2-3-induction-therapy-in-newly-diagnosed-aml-results-from-the-sal-module-phase-i-study
#15
JOURNAL ARTICLE
Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D Baldus, Martin Bornhäuser
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m2 GO in combination with '7 + 3' induction were evaluated. Based on safety findings in 12 patients, our results show that 3 mg/m2 GO on Days 1 + 4 and 100 mg midostaurin on Days 8-21 can be safely combined with IC in newly diagnosed AML...
April 9, 2024: British Journal of Haematology
https://read.qxmd.com/read/38590088/the-car-t-cell-race-the-rules-of-the-game
#16
JOURNAL ARTICLE
Adriana Balduzzi
The management of paediatric patients with refractory acute lymphoblastic leukaemia eligible for the CAR T cell product tisagenlecleucel involves multiple decision points between the process of patient referral to product infusion. How to address the individual patient's circumstances, optimize apheresis yields and, above all, plan the best bridging chemotherapy is clearly detailed in these comprehensive and practical recommendations by Kumar Mishra and colleagues. Commentary on: Mishra et al. Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia...
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38590024/kabuki-syndrome-complicated-by-severe-immune-thrombocytopenia-and-autoimmune-thyroiditis-identification-of-a-novel-pathogenic-mutation
#17
LETTER
Xinmiao Qu, Feng Xue, Wei Liu, Yunfei Chen, Mankai Ju, Ting Sun, Huan Dong, Xinyue Dai, Wenjing Gu, Huiyuan Li, Wentian Wang, Ying Chi, Renchi Yang, Xiaofan Liu, Lei Zhang, Rongfeng Fu
No abstract text is available yet for this article.
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38590011/prevalence-of-massively-diluted-bone-marrow-cell-samples-aspirated-from-patients-with-myelodysplastic-syndromes-mds-or-suspected-of-mds-a-retrospective-analysis-of-nationwide-samples-in-japan
#18
JOURNAL ARTICLE
Kiyoyuki Ogata, Yuto Mochimaru, Nana Kasai, Kazuma Sei, Naoya Kawahara, Mika Ogata, Yumi Yamamoto
Bone marrow (BM) examination is a key element in the diagnosis and prognostic grading of myelodysplastic syndromes (MDSs), and obtaining adequate BM cell samples is critical for accurate test results. Massive haemodilution of aspirated BM samples is a well-known problem; however, its incidence in patients with MDS has not been well studied. We report the first study to examine the incidence of massive haemodilution in nationwide BM samples aspirated from patients diagnosed with or suspected of MDS in Japan...
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38586911/essential-thrombocythaemia-a-contemporary-approach-with-new-drugs-on-the-horizon
#19
REVIEW
Francisca Ferrer-Marín, Juan Carlos Hernández-Boluda, Alberto Alvarez-Larrán
Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET-thrombosis scoring system, which accounts for the increased risk linked to the JAK2 mutation, has been incorporated into most expert recommendations...
April 8, 2024: British Journal of Haematology
https://read.qxmd.com/read/38581290/letermovir-prophylaxis-reduced-cytomegalovirus-reactivation-and-resistance-post-umbilical-cord-blood-transplantation
#20
JOURNAL ARTICLE
Bingbing Yan, Guangyu Sun, Yue Wu, Weiwei Wu, Kaidi Song, Yaxin Cheng, Aijie Huang, Tianzhong Pan, Baolin Tang, Xiaoyu Zhu
To explore the impact of letermovir (LET) prophylaxis on cytomegalovirus (CMV) reactivation and resistance in both adult and paediatric umbilical cord blood transplantation (UCBT) patients, we retrospectively compared 43 UCBT patients who received LET as CMV prophylaxis with a historical cohort of 207 UCBT patients without LET usage. LET was administered from Day +1 to Day +100. The 180-day cumulative incidence of CMV reactivation (47.3% vs. 74.4%, p < 0.001) and the proportion of refractory CMV reactivation (15...
April 6, 2024: British Journal of Haematology
journal
journal
20057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.